Ideas & Impact › Resources › Accelerating Access to Optimal Child-Friendly Antiretroviral Formulations

While clinical trials have demonstrated the benefits of Dolutegravir (DTG) and Lopinavir-Ritonavir (LPV/r) over Nevirapine (NVP)-based regimens, many children are still on NVP-based regimens. Even when LPV/r syrup is available, it is poorly tolerated by children and difficult to store due to its cold chain requirement. This brief provides an overview of EGPAF’s continued work under Unitaid’s POC EID grant to accelerate sustainable access to optimal pediatric ARV formulations in five implementing countries, Côte d’Ivoire, Eswatini, Lesotho, Mozambique and Zimbabwe.

Explore Related Resources

Search More Resources

Resource

Effectiveness of a Multi-component Facility-based Intervention on HIV-related Infant and Maternal Outcomes

Published April 2025

Introduction Even in the context of widespread access to prevention of vertical HIV transmission (PVT) services, health system challenges compromise health outcomes for women living with HIV and their children. The “Integrated Management Team to Improve Maternal-Child Outcomes” (IMPROVE) study measured the effect of a package of facility-based interventions on PVT and maternal and child […]

Countries:

Lesotho

newborn baby held by mother in Eswatini

Journal Articles

Birth Defects and Adverse Pregnancy Outcomes in Hospital-based Birth Surveillance in Eswatini

Published February 2025

Background The Botswana Tsepamo study identified an initial neural tube defect (NTD) safety signal with dolutegravir antiretroviral therapy (ART) exposure at conception. We conducted similar surveillance in 5 hospitals in Eswatini from September 2021 to September 2023 to evaluate the prevalence of birth defects and adverse pregnancy outcomes by maternal HIV status and ART regimen/timing. […]

Countries:

Eswatini

Journal Articles

HIV Drug Resistance Profile in Clients Experiencing Treatment Failure After the Transition to a Dolutegravir-Based First-Line Antiretroviral Treatment Regimen in Mozambique

Published January 2025

Real-world data on HIV drug resistance (HIVDR) after transitioning to tenofovir disoproxil fumarate/lamivudine/dolutegravir (TLD) are limited. We assessed HIVDR rates and patterns in clients with virological failure (VF) after switching from an NNRTI-based regimen to TLD. A cross-sectional study was conducted in Gaza, Mozambique (August 2021–February 2022), including adults on first-line ART for ≥12 months […]

Topics:

HIV

Countries:

Mozambique